Literature DB >> 28971838

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.

Nicolai J Wewer Albrechtsen1,2, Anders E Junker3, Mette Christensen4, Sofie Hædersdal3, Flemming Wibrand4, Allan M Lund4, Katrine D Galsgaard1,2, Jens J Holst1,2, Filip K Knop2,3,5, Tina Vilsbøll3,5,6.   

Abstract

Patients with type 2 diabetes (T2D) and patients with nonalcoholic fatty liver disease (NAFLD) frequently exhibit elevated plasma concentrations of glucagon (hyperglucagonemia). Hyperglucagonemia and α-cell hyperplasia may result from elevated levels of plasma amino acids when glucagon's action on hepatic amino acid metabolism is disrupted. We therefore measured plasma levels of glucagon and individual amino acids in patients with and without biopsy-verified NAFLD and with and without type T2D. Fasting levels of amino acids and glucagon in plasma were measured, using validated ELISAs and high-performance liquid chromatography, in obese, middle-aged individuals with I) normal glucose tolerance (NGT) and NAFLD, II) T2D and NAFLD, III) T2D without liver disease, and IV) NGT and no liver disease. Elevated levels of total amino acids were observed in participants with NAFLD and NGT compared with NGT controls (1,310 ± 235 µM vs. 937 ± 281 µM, P = 0.03) and in T2D and NAFLD compared with T2D without liver disease (1,354 ± 329 µM vs. 511 ± 235 µM, P < 0.0001). Particularly amino acids with known glucagonotropic effects (e.g., glutamine) were increased. Plasma levels of total amino acids correlated to plasma levels of glucagon also when adjusting for body mass index (BMI), glycated hemoglobin (HbA1c), and cholesterol levels (β = 0.013 ± 0.007, P = 0.024). Elevated plasma levels of total amino acids associate with hyperglucagonemia in NAFLD patients independently of glycemic control, BMI or cholesterol - supporting the potential importance of a "liver-α-cell axis" in which glucagon regulates hepatic amino acid metabolism. Fasting hyperglucagonemia as seen in T2D may therefore represent impaired hepatic glucagon action with increasing amino acids levels. NEW &amp; NOTEWORTHY Hypersecretion of glucagon (hyperglucagonemia) has been suggested to be linked to type 2 diabetes. Here, we show that levels of amino acids correlate with levels of glucagon. Hyperglucagonemia may depend on hepatic steatosis rather than type 2 diabetes.

Entities:  

Keywords:  amino acids; glucagon; hyperglucagonemia; nonalcoholic liver disease; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28971838     DOI: 10.1152/ajpgi.00216.2017

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  15 in total

1.  Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.

Authors:  Nicolai J Wewer Albrechtsen; Kristine Færch; Troels M Jensen; Daniel R Witte; Jens Pedersen; Yuvaraj Mahendran; Anna E Jonsson; Katrine D Galsgaard; Marie Winther-Sørensen; Signe S Torekov; Torsten Lauritzen; Oluf Pedersen; Filip K Knop; Torben Hansen; Marit E Jørgensen; Dorte Vistisen; Jens J Holst
Journal:  Diabetologia       Date:  2018-01-05       Impact factor: 10.122

Review 2.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.

Authors:  Amélio F Godoy-Matos; Wellington S Silva Júnior; Cynthia M Valerio
Journal:  Diabetol Metab Syndr       Date:  2020-07-14       Impact factor: 3.320

3.  Gastric Bypass with Different Biliopancreatic Limb Lengths Results in Similar Post-absorptive Metabolomics Profiles.

Authors:  Ivana Jarak; Sofia S Pereira; Rui A Carvalho; Pedro F Oliveira; Marco G Alves; Marta Guimarães; Nicolai J Wewer Albrechtsen; Jens J Holst; Mário Nora; Mariana P Monteiro
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

4.  A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.

Authors:  Carolina B Lobato; Sofia S Pereira; Marta Guimarães; Bolette Hartmann; Nicolai J Wewer Albrechtsen; Linda Hilsted; Jens J Holst; Mário Nora; Mariana P Monteiro
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-30       Impact factor: 5.555

5.  The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.

Authors:  Christina Gar; Stefanie J Haschka; Stefanie Kern-Matschilles; Barbara Rauch; Vanessa Sacco; Cornelia Prehn; Jerzy Adamski; Jochen Seissler; Nicolai J Wewer Albrechtsen; Jens J Holst; Andreas Lechner
Journal:  Diabetologia       Date:  2020-12-04       Impact factor: 10.122

6.  The liver-alpha-cell axis after a mixed meal and during weight loss in type 2 diabetes.

Authors:  Julia Otten; Andreas Stomby; Maria Waling; Elin Chorell; Mats Ryberg; Michael Svensson; Jens Juul Holst; Tommy Olsson
Journal:  Endocr Connect       Date:  2021-09-09       Impact factor: 3.335

Review 7.  Integrating the inputs that shape pancreatic islet hormone release.

Authors:  Glyn M Noguchi; Mark O Huising
Journal:  Nat Metab       Date:  2019-12-13

8.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

Review 9.  Biomarkers for type 2 diabetes.

Authors:  Markku Laakso
Journal:  Mol Metab       Date:  2019-09       Impact factor: 7.422

10.  Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study.

Authors:  Paula Fernandez-Guerra; Ana C Gonzalez-Ebsen; Susanne E Boonen; Julie Courraud; Niels Gregersen; Jesper Mehlsen; Johan Palmfeldt; Rikke K J Olsen; Louise Schouborg Brinth
Journal:  Biomolecules       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.